• Explore /
  • Poster
  • / Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.

Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.

Abstract Video & Slides Poster

Authors

null

Raffit Hassan

Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Raffit Hassan , Marcus O. Butler , David Yoonsuk Oh , Roisin Eilish O'Cearbhaill , Lauren MacMullen , Erin Jeter , Udayan Guha , Viera P. Muzithras , Kevin Zikaras , Melissa Lynne Johnson , Janos Laszlo Tanyi , Azam Ghafoor , Robert Tighe , Munisha Smalley , Alfonso Quintas-Cardama , David S. Hong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT03907852

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8537)

DOI

10.1200/JCO.2023.41.16_suppl.8537

Abstract #

8537

Poster Bd #

164

Abstract Disclosures

Similar Posters

First Author: Andreas Nicholas Saltos

First Author: Elio Adib

Poster

2020 ASCO Virtual Scientific Program

Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.

Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.

First Author: Tara Elisabeth Seery

First Author: Manish R. Patel